With HGF mimetics currently in phase II clinical trials for treating myocardial infarction and kidney dysfunction, our results suggest that these drugs might also be used to control chronic inflammation in muscular dystrophy and other inflammatory myopathies without compromising host immunity. This evidence concerns the gene HGF and myocardial infarction.